Most Surveyed MCO Pharmacy Directors Do Not Place Cost Control Measures on Branded Antiretroviral Drugs, According to a New Report from Decision
WALTHAM, Mass., Aug. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the expansion of labeling for Merck's Isentress to include use in treatment naive patients will significantly impact sales of the drug for HIV treatment as half of surveyed physicians expect to replace between six percent and 15 percent of their prescriptions for Bristol-Myers Squibb's Sustiva with Isentress. In 2007, 17 percent of first-line patients were treated with Sustiva, according to surveyed physicians.
The new Physician & Payer Forum primary market research report entitled Novel HIV Therapies: Physician and Payer Perspective on Recently Launched and Emerging Antiretrovirals finds that surveyed infectious disease specialists estimate that they will prescribe Isentress to more than 11 percent of their first-line patients if the drug is indicated for this patient population. Additionally, the report finds that most surveyed managed care organizations' (MCO) pharmacy directors do not place cost controls on many of the branded antiretroviral products that are covered in their private health plans. As a result, most antiretroviral drugs -- including Isentress and Sustiva -- will not be subjected to new cost control measures over the next 12 months, according to more than 80 percent of MCO pharmacy directors surveyed.
The report also finds that, in order to compete more effectively with
other antiretroviral drugs, surveyed physicians indicate that drugs in the
CCR5 antagonist class will need to overcome hurdles associated with the
medically necessary test that is used to determine patient eligibility for
CCR5 antagonist drug treatment. Physicians consider the prerequisite
|SOURCE Decision Resources|
Copyright©2008 PR Newswire.
All rights reserved